PFS in the gBRCAmut cohort1
aCensored subjects are indicated by closed circles.
Similar magnitude of benefit within key demographic and prognostic subgroups2
CR, complete response; gBRCAmut, germline BRCA mutated; HR, hazard ratio; PFS, progression-free survival; PR, partial response.
References: 1. ZEJULA (niraparib) [package insert]. Waltham, MA: TESARO, Inc.; October 2019. 2. Mirza MR, Monk BJ, Herrstedt J, et al; ENGOT-OV16/NOVA investigators. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154-2164, and Supplementary Appendix. 3. Matulonis UA, Herrstedt J, Tinker AV, et al. Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC). Poster presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, IL. Poster 5534. 4. Data on file. TESARO, Inc.